Immuneering Corporation (NASDAQ:IMRX) Director Acquires $89,471.85 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Thomas J. Schall bought 40,485 shares of the stock in a transaction on Tuesday, June 17th. The shares were purchased at an average price of $2.21 per share, with a total value of $89,471.85. Following the acquisition, the director now owns 43,385 shares in the company, valued at approximately $95,880.85. This represents a 1,396.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Immuneering Stock Performance

IMRX traded up $0.47 on Wednesday, hitting $2.29. 3,128,825 shares of the company were exchanged, compared to its average volume of 2,445,076. The stock's fifty day moving average is $1.53 and its 200-day moving average is $1.74. Immuneering Corporation has a 12 month low of $1.00 and a 12 month high of $3.83. The company has a market cap of $82.27 million, a PE ratio of -1.17 and a beta of 0.01.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). As a group, equities research analysts expect that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. acquired a new stake in Immuneering in the fourth quarter valued at $390,000. First Manhattan CO. LLC. bought a new stake in shares of Immuneering in the 4th quarter valued at about $71,000. Bridgeway Capital Management LLC raised its holdings in shares of Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after purchasing an additional 22,400 shares during the period. Marshall Wace LLP acquired a new stake in Immuneering in the 4th quarter valued at about $47,000. Finally, XTX Topco Ltd grew its holdings in Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after purchasing an additional 20,871 shares during the period. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IMRX shares. Mizuho upped their price objective on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Immuneering in a research note on Wednesday. Oppenheimer decreased their price target on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Chardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Immuneering currently has a consensus rating of "Moderate Buy" and an average target price of $13.25.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.